Abstract
Beneficial bacteria are becoming ever more popular gene delivery method for hypoxia-tumor targeting in vivo. In this study we investigated the therapeutic effect of new recombinant Bifidobacterium breve strain expressing interleukin (IL)-24 gene (B. breve-IL24) on head and neck tumor xenograft in mice. Briefly, B. breve transformants were obtained through electro-transformation. Bacteria-tumor-targeting ability were analyzed in vivo over different time points (1, 3 and 7 days post-bacteria injection). Furthermore, the therapeutic effect of bacteria on tumor cells in vivo were analyzed as follows: 30 Balb/c nude mice bearing subcutaneous tumor were randomly divided in three groups (Drug group, green fluorescent protein (GFP) group and Saline group). The therapy lasted for 2 weeks and included B. breve-IL24 administration via tail vein for Drug group, B. breve-GFP for GFP group and phosphate buffered saline for Saline group. The tumor growth was monitored using standard caliper technique, while the apoptosis induction in vivo was analyzed by Real-time Positron Emission Tomography/Computed Tomography (PET/CT) imaging ([18F]-ML-10 tracer). At the end of the experiment, tumor tissues were collected and analyzed by western blotting. Briefly, our results suggested that our new recombinant bacterium has the capability of targeting tumor tissue in vivo. As for the therapeutic effect, our new strain has revealed to be a promising therapeutic approach against tumor growth in vivo. Briefly, higher tumor growth inhibition and higher tumor cell apoptosis induction were observed in Drug group compared with the GFP and Saline groups. To conclude, a new recombinant strain B. breve-IL24 offers a novel, safe and clinically acceptable therapeutic approach for tumor therapy in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Song WJ, Du JZ, Sun TM, Zhang PZ, Wang J . Gold nanoparticles capped with polyethyleneimine for enhanced siRNA delivery. Small 2010; 6: 239–246.
Karlsen TA, Brinchmann JE . Liposome delivery of microRNA-145 to mesenchymal stem cells leads to immunological off-target effects mediated by RIG-I. Mol Ther 2013; 21: 1169–1181.
Mingozzi F, High KA . Immune responses to AAV vectors: overcoming barriers to successful gene therapy. Blood 2013; 122: 23–36.
Svoboda MG . Cultuiring cancer in the american century. Bull Sci Technol Soc 1999; 19: 219–230.
Ryan RM, Green J, Lewis CE . Use of bacteria in anti-cancer therapies. BioEssays 2006; 28: 84–94.
Osswald A, Sun Z, Grimm V, Ampem G, Riegel K, Westendorf AM et al. Three-dimensional tumor spheroids for in vitro analysis of bacteria as gene delivery vectors in tumor therapy. Micro Cell Fact 2015; 14: 199.
Yu B, Yang M, Shi L, Yao Y, Jiang Q, Li X et al. Explicit hypoxia targeting with tumor suppression by creating an 'obligate' anaerobic Salmonella Typhimurium strain. Sci Rep UK 2012; 2: 436.
Mengesha A, Wei JZ, Zhou SF, Wei MQ . Clostridial spores to treat solid tumours - potential for a new therapeutic modality. Curr Gene Ther 2010; 10: 15–26.
Dietrich G, Bubert A, Gentschev I, Sokolovic Z, Simm A, Catic A et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nat Biotechnol 1998; 16: 181–185.
Zhu H, Li Z, Mao S, Ma B, Zhou S, Deng L et al. Antitumor effect of sFlt-1 gene therapy system mediated by Bifidobacterium Infantis on Lewis lung cancer in mice. Cancer Gene Ther 2011; 18: 884–896.
Yazawa K, Fujimori M, Amano J, Kano Y, Taniguchi S . Bifidobacterium longum as a delivery system for cancer gene therapy: selective localization and growth in hypoxic tumors. Cancer Gene Ther 2000; 7: 269–274.
Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ et al. Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther 2003; 10: 105–111.
Hidaka A, Hamaji Y, Sasaki T, Taniguchi S, Fujimori M . Exogenous cytosine deaminase gene expression in Bifidobacterium breve I-53-8w for tumor-targeting enzyme/prodrug therapy. Biosci Biotechnol Biochem 2007; 71: 2921–2926.
Lin C, Liu H, Li L, Zhu Q, Liu H, Ji Z et al. MDA-7/IL-24 inhibits cell survival by inducing apoptosis in nasopharyngeal carcinoma. Int J Clin Exp Med 2014; 7: 4082–4090.
Gopalan B, Shanker M, Chada S, Ramesh R . MDA-7/IL-24 suppresses human ovarian carcinoma growth in vitro and in vivo. Mol Cancer 2007; 6: 11.
Dash R, Bhoopathi P, Das SK, Sarkar S, Emdad L, Dasgupta S et al. Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res 2014; 74: 563–574.
Bhutia SK, Das SK, Azab B, Menezes ME, Dent P, Wang XY et al. Targeting breast cancer-initiating/stem cells with melanoma differentiation-associated gene-7/interleukin-24. Int J Cancer 2013; 133: 2726–2736.
Zhang X, Kang X, Shi L, Li J, Xu W, Qian H et al. mda-7/IL-24 induces apoptosis in human HepG2 hepatoma cells by endoplasmic reticulum stress. Oncol Rep 2008; 20: 437–442.
Bhutia SK, Das SK, Kegelman TP, Azab B, Dash R, Su ZZ et al. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. J Cell Physiol 2012; 227: 1805–1813.
Wang L, Feng Z, Wu H, Zhang S, Pu Y, Bian H et al. Melanoma differentiation-associated gene-7/interleukin-24 as a potential prognostic biomarker and second primary malignancy indicator in head and neck squamous cell carcinoma patients. Tumor Biol 2014; 35: 10977–10985.
Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC . Cutting edge: STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol 2001; 167: 3545–3549.
Menezes ME, Bhatia S, Bhoopathi P, Das SK, Emdad L, Dasgupta S et al. MDA-7/IL-24: multifunctional cancer killing cytokine. Adv Exp Med Biol 2014; 818: 127–153.
O'Connell Motherway M, O'Driscoll J, Fitzgerald GF, Van Sinderen D . Overcoming the restriction barrier to plasmid transformation and targeted mutagenesis in Bifidobacterium breve UCC2003. Microb Biotechnol 2009; 2: 321–332.
Dinoto A, Suksomcheep A, Ishizuka S, Kimura H, Hanada S, Kamagata Y et al. Modulation of rat cecal microbiota by administration of raffinose and encapsulated Bifidobacterium breve. Appl Environ Microbiol 2006; 72: 784–792.
Trojanova I, Vlkova E, Rada V, Marounek M . Different utilization of glucose and raffinose in Bifidobacterium breve and Bifidobacterium animalis. Folia Microbiol 2006; 51: 320–324.
Cronin M, Akin AR, Collins SA, Meganck J, Kim JB, Baban CK et al. High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One 2012; 7: e30940.
Cronin M, Morrissey D, Rajendran S, El Mashad SM, van Sinderen D, O'Sullivan GC et al. Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther 2010; 18: 1397–1407.
Vuletic ARaJL. I . Whole-body imaging of bacteria expressing mKate2 fluorescence. J Med Bioeng 2015; 4: 5.
Hoglund J, Shirvan A, Antoni G, Gustavsson SA, Langstrom B, Ringheim A et al. 18F-ML-10, a PET tracer for apoptosis: first human study. J Nucl Med 2011; 52: 720–725.
Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 2015; 350: 1084–1089.
Pradelli LA, Beneteau M, Ricci JE . Mitochondrial control of caspase-dependent and -independent cell death. Cell Mol Life Sci 2010; 67: 1589–1597.
Alvarez-Martin P, Belen Florez A, Margolles A, del Solar G, Mayo B . Improved cloning vectors for bifidobacteria, based on the Bifidobacterium catenulatum pBC1 replicon. Appl Environ Microbiol 2008; 74: 4656–4665.
Y. Gui Z, Xa X Z . Synthesis precursor of apoptosis imaging agent ~(18)F-ML-10 and its radiolabing with ~(18)F. J Nuclear Radiochem 2016; 38: 3.
Acknowledgements
The plasmids in this work were constructed in ACTA by Lin Wang. We thank Professor Douwe van Sinderen and Dr Mary O’Connell Motherway for their help in the transformation of B. breve. This study was funded by the National Key Instrumentation Development Project (2011YQ030114) and National Natural Science Foundation of China (number 81470707 and number 81371593), Beijing Natural Science Foundation (number 7162113), as well as Peking University School and Hospital of Stomatology Youth Research Fund (number PKUSS20160108).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on Gene Therapy website
Supplementary information
Rights and permissions
About this article
Cite this article
Wang, L., Vuletic, I., Deng, D. et al. Bifidobacterium breve as a delivery vector of IL-24 gene therapy for head and neck squamous cell carcinoma in vivo. Gene Ther 24, 699–705 (2017). https://doi.org/10.1038/gt.2017.74
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/gt.2017.74
This article is cited by
-
The tumor ecosystem in head and neck squamous cell carcinoma and advances in ecotherapy
Molecular Cancer (2023)
-
Current advances in microbial-based cancer therapies
Medical Oncology (2023)
-
Bifidobacteria in Fermented Dairy Foods: A Health Beneficial Outlook
Probiotics and Antimicrobial Proteins (2023)
-
Feasibility between Bifidobacteria Targeting and Changes in the Acoustic Environment of tumor Tissue for Synergistic HIFU
Scientific Reports (2020)
-
Experimental Study of Retention on the Combination of Bifidobacterium with High-Intensity Focused Ultrasound (HIFU) Synergistic Substance in Tumor Tissues
Scientific Reports (2019)